Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Fluorescence lifetime imaging of 5-ALA-induced PpIX and autofluorescence for detecting infiltrating glioblastoma margins in patients.

Biomedical optics express·2026

Same author

High-Density Multi-Depth Human Recordings Using 45 mm Long Neuropixels Probes.

ArXiv·2026

Same author

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Journal of neuro-oncology·2026

Same author

Pharmacokinetics of lidocaine infusion during surgery for glioblastoma.

Clinical neurology and neurosurgery·2025

Same author

Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma.

Metabolites·2025

Same author

Label-free fluorescence lifetime imaging for real-time guidance of stereotactic biopsy: A feasibility study in brain cancer patients.

Neuro-oncology advances·2025

Search research articles

Related Experiment Video

Updated: Apr 20, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Immunotherapy for malignant gliomas.

¹Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine, 676 N. St. Clair Street, Suite 2210, Chicago, IL, 60611, USA, orin.bloch@northwestern.edu.

Cancer Treatment and Research

|December 4, 2014

Summary

Cancer immunotherapy offers a promising, less toxic treatment for malignant gliomas by leveraging the immune system. Future strategies combine active vaccination with immune checkpoint inhibitors to overcome tumor-induced immunosuppression and improve survival.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Apr 20, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Area of Science:

Neuro-oncology
Immunology
Cancer Research

Background:

Cancer immunotherapy harnesses the immune system to target cancer cells, offering a potentially less toxic and more specific treatment for malignant gliomas compared to chemotherapy.
Immunotherapy can provide sustained efficacy through the induction of immunologic memory.
Current glioma immunotherapy primarily focuses on active vaccination against tumor-specific antigens, with early trials showing promise but lacking survival benefit in randomized controlled trials.

Purpose of the Study:

To review the current landscape of cancer immunotherapy for malignant gliomas.
To identify the major barriers to effective glioma immunotherapy, particularly tumor-induced immunosuppression.
To explore future directions for glioma immunotherapy, including combination strategies.

Main Methods:

Review of existing literature on cancer immunotherapy, focusing on malignant gliomas.
Analysis of mechanisms underlying tumor-induced immunosuppression in gliomas, including regulatory T cells, PD-L1 expression, and CTLA-4 signaling.
Evaluation of immunomodulatory agents and their efficacy in combating immunosuppression.

Main Results:

While active vaccination strategies have shown promising early results, no glioma immunotherapy has yet demonstrated improved survival in randomized controlled trials.
Tumor-induced immunosuppression is a significant barrier, involving complex mechanisms like regulatory T cells, PD-L1, and CTLA-4.
Immunomodulatory agents are effective in other cancers and are being investigated for glioma treatment.

Conclusions:

The future of malignant glioma immunotherapy likely involves a combination approach.
Combining active vaccination with immune checkpoint inhibition (targeting factors like PD-L1 and CTLA-4) holds significant potential.
Overcoming tumor-induced immunosuppression is critical for advancing glioma immunotherapy and improving patient survival.